首頁 > 市場調查報告書 > 醫療設備

體外診斷孤兒藥

市場調查報告書

商品編碼

2126420

罕見癌症診斷市場－策略分析與預測（2026-2035）

Rare Oncology Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計罕見癌症診斷市場將從 2026 年的 65.7 億美元成長到 2035 年的 174.5 億美元，複合年成長率為 11.5%。

全球罕見癌症診斷市場正經歷強勁成長，這主要得益於精準醫療的擴展以及對罕見癌症進行全面分子特徵分析需求的日益成長。該市場涵蓋用於診斷罕見惡性腫瘤（例如肉瘤、神經內分泌腫瘤、罕見中樞神經系統腫瘤、胸腺惡性腫瘤、罕見血液系統惡性腫瘤和卵巢生殖細胞腫瘤）的儀器、試劑和試劑盒、軟體和資訊科學以及相關服務。由於傳統的組織病理學評估往往無法區分需要不同治療方法的基因不同的腫瘤亞型，因此診斷需求越來越側重於全面的分子譜分析。隨著基於生物標記的療法越來越依賴治療前已檢驗的分子證據，醫療系統正在擴展其基因組檢測能力。監管機構、腫瘤學會和製藥公司不斷強調精準診斷的重要性，因為伴隨診斷測試在確定標靶治療和免疫療法的適用性方面發揮著越來越關鍵的作用。這些結構性發展正在將罕見癌症診斷確立為個人化癌症治療的重要組成部分。

市場促進因素

精準腫瘤學的廣泛應用

精準腫瘤學正成為重要的成長要素，因為治療決策越來越依賴全面的分子特徵分析，而不僅僅依賴腫瘤的組織學觀察。隨著臨床醫生需要在開立標靶治療或免疫療法處方前識別出具有治療意義的突變，基因組分析的需求正在轉向基因組分析。傳統的診斷方法往往無法捕捉罕見癌症的分子複雜性，這限制了個人化治療的機會。醫療機構正在擴展其定序能力，並將伴隨診斷整合到常規腫瘤診療流程中，以改善臨床決策。這種轉變持續推動對先進罕見癌症診斷技術的需求。

擴大伴隨診斷的開發

隨著標靶癌症療法的法規核准越來越要求在治療開始前檢驗的生物標記檢測，伴隨診斷正發揮至關重要的作用。製藥公司在拓展精準醫療產品線的同時，也正在開發診斷檢測方法以識別合格的患者群體。序貫生物標記檢測不僅會延遲治療的開始，而且當需要進行多項檢測時，還會增加檢查室的負擔。診斷設備製造商正在推出多分子平台，這些平台可以在單一工作流程中評估多種具有臨床意義的生物標記。這種發展趨勢正在不斷加速綜合癌症診斷技術的應用。

對全面基因組分析的需求日益成長

全面的基因組分析有助於改善臨床管理，因為罕見癌症通常會表現出多種分子突變，這些突變會影響治療反應和疾病預後。隨著腫瘤學家尋求超越單一基因突變的更廣泛的基因組信息，醫療機構正在增加對次世代定序平台的投資。單基因檢測不僅提供的臨床資訊有限，還會降低精準腫瘤學計畫的效率。檢查室正在採用整合定定序和生物資訊解決方案，以提供標準化的基因組分析結果並縮短結果獲取時間。這些進步將持續推動市場的持續成長。

擴大罕見癌症調查計畫

隨著科學知識的不斷深入，新型生物標記和具有臨床意義的基因組標靶在罕見癌症中不斷被發現，研究持續推動診斷技術的創新。學術癌症中心、生技公司和製藥公司正在拓展癌症研究合作檢驗，同時也正在驗證先進的分子診斷舉措。歷史上，生物學知識的匱乏限制了許多罕見惡性腫瘤的診斷準確性。研究人員正在整合基因組學、轉錄組學、蛋白質組學和數位病理學，以改善疾病分類和生物標記的發現。因此，科學的持續進步正在推動對腫瘤特異性診斷的長期需求。

市場限制因素

全面的基因測序、多生物標記檢測和先進的病理平台的高成本仍然是許多醫療保健系統採用這些技術的障礙。分子病理學專業知識的匱乏導致診斷延誤，並造成對複雜基因組觀察解讀不一致。針對晚期腫瘤診斷的報銷政策差異也持續限制這些技術在各國醫療保健市場的普及。此外，將全面的基因組分析整合到常規臨床工作流程中的複雜性也為許多檢查室帶來了營運方面的挑戰。

依產品
- 裝置
- 試劑和試劑盒
- 軟體與資訊科學
- 服務
透過技術
- 次世代定序（NGS）
- 聚合酵素鏈鎖反應（PCR）
- 螢光原位雜合反應（FISH）
- 免疫組織化學（IHC）
- 液態生物檢體
- 流式細胞技術
- 其他分子診斷技術
按癌症類型
- 肉瘤
- 神經內分泌腫瘤（NETs）
- 神經膠質瘤和罕見的中樞神經系統腫瘤
- 惡性胸腺腫瘤
- 罕見骨髓惡性腫瘤
- 卵巢生殖細胞腫瘤
- 其他罕見癌症適應症
依檢體類型
- 組織切片檢查
- 血
- 骨髓
- 其他生物檢體
最終用戶
- 醫院
- 獨立診斷實驗室
- 癌症研究機構
- 專業腫瘤中心

第10章：罕見癌症診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：罕見癌症診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
韓國
澳洲
印度
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Illumina, Inc.
QIAGEN NV
Agilent Technologies, Inc.
Danaher Corporation
Bio-Rad Laboratories, Inc.
Guardant Health, Inc.
Exact Sciences Corporation
Foundation Medicine, Inc.
NeoGenomics Laboratories, Inc.
Laboratory Corporation of America Holdings（Labcorp）
Quest Diagnostics Incorporated
Tempus AI, Inc.
Myriad Genetics, Inc.

第14章：罕見癌症診斷市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009131

The Rare Neurological Disease Diagnostics Market is anticipated to grow at a CAGR of 11.5% from USD 6.57 billion in 2026 to USD 17.45 billion in 2035.

The global rare oncology diagnostics market is experiencing robust growth, driven by the expansion of precision medicine and the increasing need for comprehensive molecular characterization of uncommon cancers. This market encompasses instruments, reagents and kits, software and informatics, and services used to diagnose rare malignancies, including sarcomas, neuroendocrine tumors, rare central nervous system tumors, thymic malignancies, rare hematologic cancers, and ovarian germ cell tumors. Diagnostic demand increasingly focuses on comprehensive molecular profiling because conventional histopathological assessment alone frequently cannot distinguish between genetically distinct tumor subtypes that require different therapeutic approaches. Healthcare systems are expanding genomic testing capabilities because biomarker-guided therapies increasingly depend on validated molecular evidence before treatment initiation. Regulatory agencies, oncology societies, and pharmaceutical companies continue emphasizing precision diagnostics because companion diagnostic testing increasingly determines eligibility for targeted therapies and immunotherapies. These structural developments position rare oncology diagnostics as a fundamental component of personalized cancer management.

Market Drivers

Increasing Adoption of Precision Oncology

Precision oncology represents a major growth driver because treatment decisions increasingly depend on comprehensive molecular characterization rather than tumor histology alone. Demand is shifting toward genomic profiling as clinicians require identification of actionable mutations before prescribing targeted therapies or immunotherapies. Conventional diagnostic pathways frequently fail to capture the molecular complexity of rare cancers, limiting personalized treatment opportunities. Healthcare providers are expanding sequencing capabilities while integrating companion diagnostics into routine oncology workflows to improve clinical decision-making. This transition continues strengthening demand for advanced rare oncology diagnostic technologies.

Growing Development of Companion Diagnostics

Companion diagnostics play a critical role because regulatory approvals for targeted oncology therapies increasingly require validated biomarker testing before treatment initiation. Pharmaceutical companies are expanding precision medicine pipelines while simultaneously developing diagnostic assays that identify eligible patient populations. Sequential biomarker testing prolongs treatment initiation and increases laboratory burden when multiple assays become necessary. Diagnostic manufacturers are introducing multiplex molecular platforms capable of evaluating several clinically relevant biomarkers within a single workflow. This evolution continues accelerating adoption of comprehensive oncology diagnostics.

Rising Demand for Comprehensive Genomic Profiling

Comprehensive genomic profiling improves clinical management because rare malignancies frequently harbor multiple molecular alterations influencing therapeutic response and disease prognosis. Healthcare institutions are increasing investment in next-generation sequencing platforms as oncologists seek broader genomic insights that extend beyond individual gene mutations. Single-gene testing limits clinical information while reducing efficiency in precision oncology programs. Laboratories are implementing integrated sequencing and bioinformatics solutions that deliver standardized genomic interpretation with improved turnaround times. These developments continue supporting sustained market growth.

Expansion of Rare Cancer Research Programs

Research activity continues driving diagnostic innovation because increasing scientific understanding is identifying novel biomarkers and clinically relevant genomic targets across uncommon cancers. Academic cancer centers, biotechnology companies, and pharmaceutical organizations are expanding collaborative oncology research initiatives while validating advanced molecular diagnostic technologies. Limited biological knowledge historically restricted diagnostic precision across numerous rare malignancies. Researchers are integrating genomics, transcriptomics, proteomics, and digital pathology to improve disease classification and biomarker discovery. Continued scientific advancement therefore reinforces long-term demand for specialized oncology diagnostics.

Market Restraints

High costs associated with comprehensive genomic sequencing, multiplex biomarker testing, and advanced pathology platforms continue limiting accessibility across several healthcare systems. Limited availability of specialized molecular pathology expertise contributes to delayed diagnosis and inconsistent interpretation of complex genomic findings. Variability in reimbursement policies for advanced oncology diagnostics continues restricting adoption across different national healthcare markets. Additionally, the complexity of integrating comprehensive genomic profiling into routine clinical workflows presents operational challenges for many laboratories.

Technology and Segment Insights

By Product

Reagents and kits account for a substantial portion of diagnostic demand because every molecular assay, sequencing workflow, and liquid biopsy analysis requires continuous reagent consumption. Instruments remain fundamental because sequencing platforms, PCR systems, and digital pathology scanners provide the analytical infrastructure necessary for precision oncology laboratories. Software and informatics are becoming increasingly important as comprehensive genomic profiling generates complex datasets requiring advanced bioinformatics and clinical interpretation tools. Diagnostic services continue expanding because healthcare providers increasingly rely on specialized reference laboratories for comprehensive molecular testing across rare cancer indications.

By Technology

Next-generation sequencing (NGS) continues representing the leading technology because comprehensive genomic profiling enables simultaneous identification of multiple clinically actionable alterations across heterogeneous rare cancers. Polymerase chain reaction (PCR) remains essential for targeted mutation analysis and rapid biomarker detection. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) continue supporting chromosomal abnormality detection and protein expression analysis within routine oncology diagnostics. Liquid biopsy is gaining widespread clinical attention because minimally invasive genomic assessment supports disease monitoring and treatment selection when tissue availability is limited. Flow cytometry and other molecular diagnostic technologies continue complementing genomic testing by improving diagnostic precision across hematologic and selected solid tumor malignancies.

By Cancer Type

Sarcomas continue generating significant diagnostic demand because their extensive molecular diversity requires comprehensive genomic characterization for accurate classification and therapeutic planning. Neuroendocrine tumors and rare central nervous system tumors are increasingly benefiting from molecular diagnostics as biomarker-driven treatment strategies expand. Rare hematologic malignancies continue requiring integrated genomic and immunophenotypic evaluation because disease classification directly influences treatment selection. Thymic malignancies and ovarian germ cell tumors are driving specialized molecular testing as research continues identifying clinically relevant biomarkers. Other rare oncology indications are increasingly utilizing comprehensive sequencing panels that improve diagnostic accuracy while supporting precision medicine and enrollment into biomarker-guided clinical trials.

By End User

Hospitals and specialty oncology centers account for a significant share of diagnostic demand because comprehensive cancer care requires integrated molecular testing infrastructure. Independent diagnostic laboratories are expanding genomic testing capabilities to support precision oncology programs. Cancer research institutes continue driving innovation through biomarker discovery and clinical validation studies.

Competitive and Strategic Outlook

The competitive landscape features established diagnostic companies and specialized genomic testing providers. F. Hoffmann-La Roche Ltd. differentiates itself through its integrated pharmaceuticals and diagnostics business model, enabling simultaneous development of targeted therapies and companion diagnostics. Thermo Fisher Scientific Inc. provides a comprehensive portfolio spanning molecular biology, genomic sequencing, and laboratory automation. Illumina, Inc. is the global leader in next-generation sequencing technologies, providing platforms that form the foundation of many precision oncology programs. QIAGEN N.V. specializes in molecular sample preparation, assay development, and bioinformatics solutions. Agilent Technologies, Inc. offers broad expertise in pathology, genomics, and laboratory automation. Danaher Corporation maintains a diversified portfolio of molecular diagnostics and genomic technologies. Bio-Rad Laboratories provides PCR and digital PCR platforms for mutation detection. Guardant Health, Inc. has built its competitive advantage around liquid biopsy technologies enabling comprehensive genomic profiling through blood-based testing.
Strategic developments include increasing collaborations between diagnostic manufacturers and pharmaceutical companies to develop companion diagnostics aligned with targeted therapies. Companies are investing in multicenter clinical studies to validate comprehensive genomic profiling panels and liquid biopsy assays. Mergers and acquisitions are enabling broader technological portfolios and geographic expansion. Product launches are focused on integrated sequencing platforms, artificial intelligence-enabled genomic interpretation, and automated laboratory workflows. Companies that successfully combine sequencing technologies, AI, digital pathology, and comprehensive clinical interpretation into unified precision oncology ecosystems are expected to strengthen their competitive positions.

Conclusion

The rare oncology diagnostics market is poised for substantial growth, driven by the expansion of precision medicine and the increasing need for comprehensive molecular characterization of uncommon cancers. The shift toward comprehensive genomic profiling, liquid biopsy, and AI-enabled interpretation is transforming clinical practice. Pharmaceutical innovation in targeted therapies is creating sustained demand for validated companion diagnostics that support patient selection and treatment monitoring. Companies that successfully integrate sequencing technologies, artificial intelligence, and digital pathology into comprehensive diagnostic solutions are expected to lead the market. Ongoing regulatory support, biomarker discovery, and expanding healthcare infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Rare Oncology Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Rare Oncology Disease Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Disease Burden & Unmet Clinical Needs
3.8 Epidemiology and Prevalence Analysis
3.9 Diagnosed Patient Population Analysis
3.10 Testing Volume Analysis
3.11 Patient Journey Analysis
3.12 Treatment Landscape

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Technology Roadmap
6.6 AI Integration in Rare Oncology Diagnostics
6.7 Digital Pathology & Digital Health Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Rare Oncology Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology

9. Rare Oncology Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Instruments
- 9.1.2 Reagents & Kits
- 9.1.3 Software & Informatics
- 9.1.4 Services
9.2 By Technology
- 9.2.1 Next-Generation Sequencing (NGS)
- 9.2.2 Polymerase Chain Reaction (PCR)
- 9.2.3 Fluorescence In Situ Hybridization (FISH)
- 9.2.4 Immunohistochemistry (IHC)
- 9.2.5 Liquid Biopsy
- 9.2.6 Flow Cytometry
- 9.2.7 Other Molecular Diagnostic Technologies
9.3 By Cancer Type
- 9.3.1 Sarcomas
- 9.3.2 Neuroendocrine Tumors (NETs)
- 9.3.3 Gliomas & Rare Central Nervous System Tumors
- 9.3.4 Thymic Malignancies
- 9.3.5 Rare Hematologic Malignancies
- 9.3.6 Ovarian Germ Cell Tumors
- 9.3.7 Other Rare Oncology Indications
9.4 By Sample Type
- 9.4.1 Tissue Biopsy
- 9.4.2 Blood
- 9.4.3 Bone Marrow
- 9.4.4 Other Biological Samples
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Independent Diagnostic Laboratories
- 9.5.3 Cancer Research Institutes
- 9.5.4 Specialty Oncology Centers